Myelofibrosis treatment drugs

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for momelotinib for the treatment of myelofibrosis.

If myelofibrosis happens on its own, it is called primary myelofibrosis; if it develops from another bone marrow disorder, it is called secondary myelofibrosis. The U.S. Food and Drug

For the treatment of patients with myelofibrosis including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia

Myelofibrosis can happen on its own (primary myelofibrosis) or it can develop from another bone marrow disorder (secondary myelofibrosis). Some people with myelofibrosis have no symptoms and might not need treatment right away. Others with more-serious forms of the disease might need aggressive treatments right away.

Myelofibrosis is most common in people between the ages of . It often produces few symptoms at first. When anemia develops, it can cause fatigue, weakness, and abdominal pain from an enlarged spleen. Myelofibrosis can occur by itself or with other blood disorders. Myelofibrosis Treatment. There are a variety of treatments for

New Drugs for the Treatment of Myelofibrosis Myelofibrosis (MF) includes primary MF and MF that has arisen from an antecedent polycythemia

Find out more about primary myelofibrosis treatment drugs @Drugs for Primary Myelofibrosis Treatment Myelofibrosis Medications. Table of

Currently, there are few Food and Drug Administration-approved drugs for the treatment of myelofibrosis. Available options provide patients

On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post polycythemia vera and post essential thrombocythemia), in adults with anemia.